翁啟惠..”台灣有八十四項新藥在人體試驗階段!” 包含外商上市前試驗??

SIC掛牌籌錢 尋生技千里馬 2011-11-02 中國時報在行政院「生技起飛、鑽石行動」方案被賦予「伯樂」任務的台灣生技整合育成中心（ＳＩＣ），終於在昨日成立，由旅美華裔生技專家蘇懷仁擔任首席顧問，負責籌募種子基金，並領導國內外顧問群發掘具有商業化潛力的研發計畫，投資開發新藥或生醫器材，以台灣品牌進軍全球生技市場。　生技整合育成中心（ＳＩＣ）成立後，行政院「生技起飛、鑽石行動」方案四大支柱已全數到位，預定在六個月內協助籌募十億種子基金及製藥型國家級創投基金。　行政院政務委員兼科技顧問組副召集人朱敬一昨日表示，建全推動轉譯研究的生技中心、成立食品藥物管理局、催生國家級生技創投和生技整合育成中心等四大支柱到位，只是第一步。但任何一個產業，不是新設了那個機構，成功就會從天上掉下來；政府必須每天不斷地回應產業需求，想辦法解決各項難題。　中央研究院長翁啟惠表示，台灣已有八十四項新藥研發在作人體試驗，進入第三期臨床試驗的十四項計畫，有七件是依照美國食品藥物管理局規範進行臨床試驗。無論是這些計畫或者是未來的研發計畫，有一件成功開發成新藥上市，台灣生技產業馬上就晉升兆元產業。ＳＩＣ成立茶會生技界產官學研重量級人物幾乎到齊，立法院長王金平也到場致賀。

兩岸基因相似度高 製藥分工共同開發5新藥???

朱敬一：兩岸合作開發新藥【2011/11/03 經濟日報】行政院政務委員朱敬一昨（2）日表示，中國大陸有14億人口，兩岸生醫產業可以合作，大陸「十二五」規劃中，目標25種新藥，兩岸可以合作開發五種新藥，這是國內生醫產業可以考慮的方向。 朱敬一昨天在第九屆華人企業領袖高峰會，以「台灣生醫產業的機會與挑戰」為題發表演說。朱敬一表示，台灣生技起飛鑽石行動方案目前已請來兩位國際級「大和尚」，一位是主導台灣生技創投（TMF）的張有德，專長醫療器材；一位是主導超級育成中心的蘇懷仁，尚缺對新藥育成有經驗的國際級「大和尚」，他將催生第二個國際級生技創投。 發展台灣生技產業，朱敬一提出四大因應作為，一、探討切入哪裡；二、跑第二棒，即實驗室至臨床二期，因需要的經費較少，加值明顯；三、成立超級育成中心；四、兩岸生醫產業合作。朱敬一指出，生技製藥的價值鏈非常長，中國大陸有14億人口，國際藥廠都想賣藥至中國大陸，在這中間台灣可以扮演角色。 朱敬一說，兩岸經濟協議（ECFA）生效，且兩岸皆華人，基因相似度（gene similarity）是全球唯一，兩岸生技製藥分工，最好是建立在gene similarity上，由於台灣病人樣本不夠，可由台灣做臨床實驗第一階段，中國大陸病人樣本多，可做臨床實驗二、三階段，這是最理想的分工。 朱敬一說，台灣已累積多年華人特有疾病研究，如肝癌、肺癌，這是很好利基，大陸「十二五」規劃中，目標25種新藥，兩岸可合作開發五種。兩岸已簽定醫藥衛生合作協議，同意加強合作，積極推動雙方技術標準及規範的協調性，以提升醫藥品的安全、有效性。朱敬一指出，在此基礎上，可進行醫藥品查驗、檢驗登記（審批）及生產管理規範檢查合作，探討逐步採用對方執行的結果。

Taiwan looks to recruit high-tech talent in U.S.

Central News Agency   2011-11-01 Taipei, Nov. 1 (CNA) Vice Minister of Economic Affairs Francis Liang is set to lead a business delegation on an eight-day visit to the Silicon Valley and Boston on Thursday. With over a thousand opportunities on offer, Liang said the trip was part of the Cabinet's 2009 goal to develop six emerging industries (biotechnology, green energy, tourism, long-term medical care, high-end agriculture, and cultural and creative industries), four smart industries, and other areas in the service industry. The four key smart industries are electric vehicles, cloud computing, green architecture, and the intellectual property industry. The Department of Investment Services (DIS) of the Ministry of Economic Affairs said a total of 30 corporations and research institutes will participate in the upcoming recruitment drive. They will be looking for senior executives, engineers, and research and development experts, the DIS said. Key research institutes involved in the trip include the Industrial Technology Research Institute, the Institute for Information Industry, Metal Industries Research and Development Centre, Taiwan Textile Research Institute, and the Development Center for Biotechnology. Meanwhile, technology companies to participate include Taiwan Semiconductor Manufacturing Company --the world's No. 1 contract chip maker, Chimei Innolux Corp., one of Taiwan's leading flat-panel makers, Macronix International Co., and United Microelectronics Corp., the world's second-largest contract chip maker. The government has been involved in foreign recruitment drives since 2003. Since that time, a total of 3,672 foreign-based talent with high-tech backgrounds have been attracted to work in Taiwan. (By Huang Chiao-wen and Ann Chen)

輔大校園內將蓋醫院!!

輔大將蓋醫院 推升周邊房價 2011年 11月03日 【馮牧群╱台北報導】內政部都市計劃委員會已通過將輔仁大學校區內5415坪土地由住宅區及宗教專區變更為醫療專區，4年後將有新醫院大樓啟用，加上明年3月捷運輔大站即將通車，醫療與交通雙重利多加持下，業者估捷運輔大站周邊房價可望漲2成。捷運加持雙利多 新北市政府城鄉發展局主任祕書邱敬斌指出，輔大醫院鄰近捷運機場線與捷運新莊線輔大站，方便就醫，輔大醫院預計2013年動工，2015年完工，隨著新莊副都心開發，人口成長，可滿足新莊、泰山民眾的醫療需求。永慶房屋幸福店店長鄭仁凱說，輔大醫院啟用及新莊線通車後，房價估漲2成。

Taiwan-China Pact to Sharpen Local Pharma Ind. Global Edge

 2011/11/02  Taipei, Nov. 2, 2011 (CENS)--The signing of a cooperation agreement between China and Taiwan regarding medical and healthcare issues will raise international competitiveness of Taiwan-made pharmaceuticals, especially in emerging markets, according to the Council for Economic Planning and Development (CEPD) of Taiwan's Cabinet. Quoting the latest report by IMS, CEPD says the global pharmaceutical market totaled US$856 billion in 2010, and the value is expected to jump to US$1.1 trillion by 2015. Over the next few years, the council says, the U.S. market share will decline to 31% by 2015 from 41% in 2005; while that of the five major European nations (Germany, France, Italy, Spain and the U.K.) will fall to 13% by 2015 from 20% in 2005. During the same period, total market share of the 17 emerging economies, including China, Brazil, India etc., is expected to climb to 28% by 2015 from only 12% in 2005. CEPD also says the emerging markets are the major drivers of global pharmaceutical consumption, due to surging economic growth and institutional changes in the nations. So the emerging markets are expected to create annual demand for US$150 billion of drugs by 2015, in which only 20% is for active pharmaceutical ingredients (API) while the rest for generic drugs. CEPD says Taiwan enacted special statues for the focal-point development of the pharmaceutical industry in Taiwan in 2007, and signed an agreement with China in 2010 for bilateral promotion of the pharmaceutical industry, with the joint efforts to enable Taiwan's pharmaceutical industry to win higher market share in the booming global market.